Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been given an average recommendation of “Buy” by the five ratings firms that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $6.80.

A number of brokerages have weighed in on CNTX. D. Boral Capital initiated coverage on shares of Context Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $9.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Context Therapeutics in a report on Monday, September 23rd. Finally, JMP Securities began coverage on shares of Context Therapeutics in a research report on Wednesday. They set an “outperform” rating and a $4.00 price target on the stock.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC grew its position in Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares in the last quarter. Ally Bridge Group NY LLC boosted its stake in shares of Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after purchasing an additional 1,160,281 shares during the period. Great Point Partners LLC acquired a new stake in Context Therapeutics during the 2nd quarter valued at $14,876,000. Affinity Asset Advisors LLC increased its stake in Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after buying an additional 1,290,323 shares during the period. Finally, Blue Owl Capital Holdings LP acquired a new position in Context Therapeutics in the 2nd quarter worth $10,348,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Trading Down 6.8 %

Context Therapeutics stock opened at $1.09 on Wednesday. The stock has a fifty day moving average price of $1.56 and a 200 day moving average price of $1.95. Context Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.75. The firm has a market capitalization of $81.75 million, a P/E ratio of -1.20 and a beta of 2.10.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). As a group, equities analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.